Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO plus PD-1 inhibitor for unresectable TP53-mutated hepatocellular carcinoma (phase II, single-arm)
ChiCTR2300073941Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and arsenic trioxide in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Objective response rate. Started Jul 2023; status: recruiting.
02
Drugs
sintilimabarsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073941.